Development of Multicenter Registry of Percutaneous Coronary Intervention for International Comparison and Quality Improvement

在本研究中，我们成功登记了来自15个中心的4150名患者。我们首先计算出血并发症发生率（定义为汞柱下降超过3g/dl），并生成统计模型来量化相关临床变量。我国患者出血并发症发生率为6%，明显高于西方患者。合并症如充血，或急性表现如急性冠状动脉综合征（ACS）与出血的高风险相关。其次，我们计算了指南推荐的二级预防药物的处方率，并注意到一些药物，如β受体阻滞剂或ACE/ arb的配用比其他药物少。最后，我们比较了ACS患者在工作日和周末入院的结果。这些研究结果已在日本心脏病学会年会上发表，并将手稿提交给同行评审期刊。此外，我们目前正在向每个参与网站提供反馈，并旨在量化其对改善结果的长期贡献。

In the present study, we successfully registered 4150 patients from 15 centers. We first calculated bleeding complication rate (defined drop of Hg of more than 3g/dl) and generated statistical model to quantify the associated clinical variables. The bleeding complication rate was observed in 6% of our patients, which was significantly higher compared to the Western patients. Comorbidities such as hemodyalisis, or acute presentation such as acute coronary syndrome (ACS) were associated with higher risk of bleeding. Second, we calculated prescription rate of guideline-recommended secondary prevention agents and noted some medications, such as beta-blockers or ACE/ARBs are dispensed less compared to others. Lastly, we compared the outcome of ACS patients admitted on weekdays with those admitted on weekend. The results of these studies have been presented in Japanese Society of Cardiology annual meeting and manuscripts are submitted to peer-review journals. Further, we are currently providing feedbacks to each participating sites and aim to quantify its long-term contribution to improved outcome.